PO.IM02.01 · 免疫学

Tumor-agnostic analysis identified pan-cancer immune archetypes and CD8⁺FoxP3⁺ cells as novel in situ predictors of survival

海报缩略图:Tumor-agnostic analysis identified pan-cancer immune archetypes and CD8⁺FoxP3⁺ cells as novel in situ predictors of survival
编号 193 展板 13 时间 4/19 02:00–05:00 区域 Section 9 主讲 Artur Mezheyeuski
分会场 Inflammation and Cancer Progression
查看完整资料 下载 PDF 登录后可访问当前开放资料 AACR 官方页面 ↗

作者与单位

Artur Mezheyeuski1, Emma Sandberg2, Max Backman3, Ali Teymur Kahraman3, Amanda Lindberg3, Carina Strell2, Hans Brunnström4, Jutta Huvila5, Malin Sund6, Fredrik Wärnberg7, Bengt Glimelius3, Ina Hrynchyk8, Siarhei Mauchanski9, Salome Khelashvili10, Klara Hammarström3, Margret Agnarsdottir3, Gemma Garcia-Vicién11, DAVID G. MOLLEVI12, Aine O´Reilly13, Sara Corvigno14, Hanna Dahlstrand3, Johan Botling15, Ulrika Segersten4, Agnieszka Krzyzanowska16, Anders Bjartell4, Jacob Elebro4, Margareta Heby4, Sebastian Lundgren4, Charlotta Hedner4, David Borg4, Jenny Brändstedt4, Hanna Sartor4, Per-Uno Malmström3, Martin Johansson15, Anna Portyanko10, Björn Nodin4, Cecilia Lindskog3, Karin Leandersson4, Karin Jirström4, Tobias Sjöblom3, Patrick Micke3

1Vall d’Hebron Institute of Research, Barcelona, Spain,2Uppsala University, Dept of Immunology, Genetics and Pathology, Uppsala, Sweden,3Uppsala University, Uppsala, Sweden,4Lund University, Lund, Sweden,5University of Turku, Turku, Finland,6Umeå University, Umeå, Sweden,7Sahlgrenska University Hospital Göteborg, Göteborg, Sweden,8City Clinical Pathologoanatomic Bureautitute (VHIR), Minsk, Belarus,9Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain,10N.N. Alexandrov National Cancer Centre of Belarus, Minsk, Belarus,11IDIBELL L'Hospitalet de Llobregat Barcelona, Barcelona, Spain,12LABORATORI DE RECERCA TRANSLACIONAL, INSTITUT CATALA D'ONCOLOGIA, BARCELONA, Spain,13Karolinska Institutet, Stockholm, Sweden,14UT MD Anderson Cancer Center, Houston, TX,15Sahlgrenska Universitety Hospital Göteborg, Göteborg, Sweden,16Lund University, Malmö, Sweden

摘要 Abstract

Immune infiltration shapes anti-tumor responses and is associated with patient outcomes. Yet, comprehensive studies comparing infiltration patterns and their clinical impact across cancer types are scarce.We profiled the tumor immune microenvironment across 16 solid tumor types from more than 2,700 patients using multiplex immunofluorescence with pathologist-curated image analysis to quantify major lymphoid and myeloid subsets and their spatial organization in situ.Across all cancer types, lung, endometrial, and high-grade serous ovarian cancers were highly infiltrated, whereas prostate and ER-positive breast cancers were comparatively “immune cold”. Cancer-agnostic consensus clustering resolved four reproducible immune archetypes with distinct outcomes, including an immune-hot group enriched for CD4, CD8, and B cells that associated with the best survival (p<0.001). Notably, the tumor type accounted for only a part of the immune contexture, as most cancers spanned multiple immune signature groups. Nevertheless, a machine-learning classifier trained on immune compositions distinguished tumor types with high accuracy (AUC = 0.96), confirming that each cancer maintains a recognizable immune imprint even among pan-cancer archetypes.Analysis of survival associations of individual cell classes revealed a rare CD8⁺FOXP3⁺ T-cell phenotype that emerged as a strongest positive prognostic factor across cancers (HR=0.79, 95%CI:[0.70-0.89], p=0.002). Single-cell RNA sequencing data indicated that CD8⁺FoxP3⁺ cells exhibit two distinct gene programs, with regulatory and cytotoxic capacities. Spatial mapping suggested context-dependency in the function of CD8⁺FoxP3⁺ cells, as their proximity to CD8 T cells was linked to better survival (enrichment at 10um: HR=0.76, 95%CI:[0.67-0.90], p=0.0006), whereas proximity to tumor cells was associated with worse prognosis (enrichment at 10um: HR=1.29, 95%CI:[1.12-1.49], p=0.0005).Together, our findings define pan-cancer immune archetypes that are both shared and disease-specific, explaining why “immune hot” and “cold” states are not synonymous with pure infiltration quantities. We identified CD8⁺FoxP3⁺ immune cells as a cell type with strong biomarker potential independent of cancer type.
利益披露 Disclosure
A. Mezheyeuski, None.. M. Backman, None.. A. T. Kahraman, None.. A. Lindberg, None.. C. Strell, None.. H. Brunnström, None.. J. Huvila, None.. M. Sund, None.. F. Wärnberg, None.. B. Glimelius, None.. I. Hrynchyk, None.. S. Mauchanski, None.. S. Khelashvili, None.. K. Hammarström, None.. M. Agnarsdottir, None.. G. Garcia-Vicién, None.. D. G. Mollevi, None.. A. O´Reilly, None.. S. Corvigno, None.. H. Dahlstrand, None.. J. Botling, None.. U. Segersten, None.. A. Krzyzanowska, None.. A. Bjartell, None.. J. Elebro, None.. M. Heby, None.. S. Lundgren, None.. C. Hedner, None.. D. Borg, None.. J. Brändstedt, None.. H. Sartor, None.. P. Malmström, None.. M. Johansson, None.. A. Portyanko, None.. B. Nodin, None.. C. Lindskog, None.. K. Leandersson, None.. K. Jirström, None.. T. Sjöblom, None.. P. Micke, None.

在会议检索中打开